A novel approach to the induction of specific cytolytic T cells in vivo.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Research in Immunology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0923-2494(90)90042-WPMID 2100017
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Class I-restricted processing and presentation of exogenous cell- associated antigen in vivo

  1990cited by this paper
• Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity

  1990cited by this paper
• Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response.

  1990cited by this paper
• Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2.

  1990cited by this paper
• Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide

  1990cited by this paper
• Multiple subsets of HIV‐specific cytotoxic T lymphocytes in humans and in mice

  1989cited by this paper
• In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine

  1989cited by this paper
• The activation of IL-2 transcription in L3T4+ and Lyt-2+ lymphocytes during virus infection in vivo.

  1989cited by this paper
• Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors

  1988cited by this paper
• Enhanced recognition of a modified peptide antigen by cytotoxic T cells specific for influenza nucleoprotein.

  1988cited by this paper
• Introduction of soluble protein into the class I pathway of antigen processing and presentation.

  1988cited by this paper
• Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice.

  1988cited by this paper
• Mutation Drift and Repertoire Shift in the Maturation of the Immune Response

  1987cited by this paper
• Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis

  1986cited by this paper
• Lymphokine-activated killer cells. Analysis of progenitors and effectors

  1986cited by this paper
• Selection of highly transfectable variant from mouse mastocytoma P815

  1985cited by this paper
• Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression

  1983cited by this paper
• Viral specificity of H-2-restricted T killer cells directed against syngeneic tumors induced by Gross, Friend, or Rauscher leukemia virus

  1979cited by this paper

• Genetically engineered mesenchymal stem cells: targeted delivery of immunomodulatory agents for tumor eradication

  2020cites this paper
• Discovery and development of therapeutic cancer vaccines.

  2007cites this paper
• Induction of T Lymphocytes Specific to Human Gastric Cancer Using HLA-A Matched Allogeneic Gastric Tumor Cells

  2003cites this paper
• Enhancement of anti-tumour immunity by transduction with a Mycobacterium tuberculosis gene.

  2001cites this paper
• Gene therapy with cytokine-transfected xenogenic cells (Vero-IL-2) in patients with metastatic solid tumors: mechanism(s) of elimination of the transgene-carrying cells

  1999cites this paper
• Model Regression in a Murine Breast Adenocarcinoma Human IL-2 Induces Complete Tumor the Costimulatory Molecule B 7-1 ( Murine ) and A Double Recombinant Adenovirus Expressing

  1998cites this paper
• A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model.

  1998cites this paper
• Immunostimulatory cytokines in somatic cells and gene therapy of cancer.

  1997cites this paper
• In vivo administration of interleukin-2 protects susceptible mice from Theiler's virus persistence

  1997cites this paper
• IL-2 gene delivery within an established murine tumor causes its regression without proliferation of preexisting antitumor-specific CTL.

  1997cites this paper
• Tumor immunotherapy by vaccination with cytokine gene transfected cells.

  1997cites this paper
• Immune response against medullary thyroid carcinoma (MTC) induced by parental and/or interleukin-2-secreting MTC cells in a rat model of human familial medullary thyroid carcinoma

  1996cites this paper
• Recurrent T cell receptor rearrangements in the cytotoxic T lymphocyte response in vivo against the p815 murine tumor

  1996cites this paper
• Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene.

  1995cites this paper
• Regression of experimental Burkitt's lymphoma induced by Epstein-Barr virus-immortalized human B cells.

  1994cites this paper
• Interleukin‐2 transfected prostate cancer cells generate a local antitumor effect in vivo

  1994cites this paper
• Immune response against tumors.

  1994cites this paper
• Clinical Trials of Immunotherapy of Cancer Utilizing Cytotoxic Cells

  1993cites this paper
• Adenoviral Interleukin-2 Gene Transfer into P815 Tumor Cells Abrogates Tumorigenicity and Induces Antitumoral Immunity in Mice

  1993cites this paper
• Identification of T cell peptides from C gamma 2ab involved in IgG2ab T cell-induced allotypic suppression. Relationship with the MHC haplotype of the suppressor T cell-donor Igha mice.

  1993cites this paper
• Countermeasures for ameliorating in‐flight immune dysfunction

  1993cites this paper
• Collaboration of helper and cytotoxic T lymphocytes

  1993cites this paper
• Lessons from T cell responses to virus induced tumours for cancer eradication in general.

  1992cites this paper
• Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer.

  1992cites this paper
• [Potentiation of the antitumoral effect of electrochemotherapy by immunotherapy with allogeneic cells producing interleukin 2].

  1992cites this paper
• [Inhibition of the tumoral growth induced by the injection of histo-incompatible cells producing interleukin-2].

  1992cites this paper
• Tumor eradication by adoptive transfer of cytotoxic T lymphocytes.

  1992cites this paper
• Inhibition of tumor growth by histoincompatible cells expressing interleukin-2.

  1992cites this paper
• IL-2 gene transduction in malignant cells: applications in cancer containment.

  1992cites this paper
• T-cell immunotherapy of cancer.

  1991cites this paper
• The Promise of T Cell Immunotherapy of Cancer

  1991cites this paper
• Immunotherapy and gene therapy of cancer.

  1991cites this paper
• Interleukin 2‐dependent activation of tumor‐specific cytotoxic T lymphocytes in vivo

  1991cites this paper